We previously covered Affimed (AFMD) in detail (part I and part II). Last week, AFMD released a Q2 2021 business update and it was mixed. AFM13 + MD Anderson collaboration in blood cancers seems to be progressing well, with data slated for ASH in December. Data for AFM24 monotherapy, on the other hand, has been vague and overall disappointing. Here ar…
© 2024 Bohdan (Bo) Khomtchouk, Ph.D.
Substack is the home for great culture